Senator Bill Cassidy’s (R-LA) letter to the US Food and Drug administration calls into question the agency’s statutory authority to regulate clinical decision support (CDS) software as a medical device.
The agency “threatens to undermine the effective use of [CDS] tools with its September 2022 final guidance,” Cassidy said.






